SOHO Italy 2020 | MDS: state of the art in Europe
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the state of the art in the treatment and management of patients with myelodysplastic syndromes (MDS) as discussed in the Society of Hematological Oncology (SOHO) Italian 2020 meeting. Prof. Santini discusses differences in treatment strategies between the US and Europe, including the possibility of treating lower-risk MDS with hypomethylating agents in the US which are not used in Europe, which reflects differences in the availability of experimental agents for patients in the US and Europe. Prof. Santini also explores the use of APR-246, a p53 targeting agent, in patients with high-risk MDS which is available in some European centers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
